• Identifying clinically useful biomarkers in neurodegenerative disease through a collaborative approach: The NeuroToolKit - January 2023
• Optimal combinations of CSF biomarkers for predicting cognitive decline and clinical conversion in cognitively unimpaired participants and mild cognitive impairment - January 2023
• Liver-specific polygenic risk score is associated with Alzheimer’s disease diagnosis - January 2023
• Neuropathology-based APOE genetic risk score better quantifies APOE effect in statistical analyses - February 2023
• The recency ratio assessed by story recall is associated with cerebrospinal fluid levels of neurodegeneration biomarkers - February 2023
• Biological brain age prediction using machine learning on structural neuroimaging data: multi-cohort validation against biomarkers of Alzheimer's disease and neurodegeneration stratified by sex - April 2023
• Identification of plasma metabolites associated with modifiable risk factors and biomarkers reflecting Alzheimer’s disease pathology - March 2023
• Large-scale proteome and metabolome analysis of CSF implicates altered glucose metabolism and succinylcarnitine in Alzheimer’s disease - May 2023
• Asthma and the lung-brain axis in cognitive decline: evidence from diffusion MRI and CSF biomarkers - June 2023
• Prevalence and Clinical Implications of a β-Amyloid–Negative, Tau-Positive Cerebrospinal Fluid Biomarker Profile in Alzheimer Disease - July 2023

• Association between air pollution exposure and biomarkers of Alzheimer’s disease: A cross-sectional study in at risk cognitively unimpaired individuals - December 2021
• CSF Synaptic Biomarkers in the Preclinical Stage of Alzheimer Disease and Their Association With MRI and PET: A Cross-sectional Study - November 2021
• Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum - October 2021
• Enhancing the Sensitivity of Memory Tests: Reference Data for the Free and Cued Selective Reminding Test and the Logical Memory Task from Cognitively Healthy Subjects with Normal Alzheimer’s Disease Cerebrospinal Fluid Biomarker Levels - September 2021
• Large-scale proteome analysis of CSF implicates altered glucose metabolism in Alzheimer’s disease - September 2021
• Amyloid positive individuals with subjective cognitive decline present increased CSF Neurofilament Light levels that relates to hippocampal volume - August 2021
• Perivascular spaces are associated with tau pathophysiology and synaptic dysfunction in early Alzheimer’s continuum - August 2021
• Insulin resistance is related to cognitive decline but not change in CSF biomarkers of Alzheimer’s disease in non-demented adults - July 2021
• Cognitively unimpaired individuals with low burden of Abeta pathology have a distinct CSF biomarker profile - July 2021
• Liver-specific polygenic risk score is more strongly associated than genome-wide score with Alzheimer’s disease diagnosis - May 2021
• Interaction of amyloid and tau on cortical microstructure in late middle-aged cognitively unimpaired adults - May 2021
• Cerebral amyloid-β burden is associated with neurodegeneration and gliosis:  Mediation by p-tau and interactions with risk factors early in the Alzheimer's continuum - March 2021
• Liver-specific polygenic risk score is more strongly associated than genome-wide score with Alzheimer’s disease diagnosis - March 2021
• Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimer’s disease - February 2021

The NeuroToolKit (NTK) is the result of an academic and industry partners to generate high quality, reproducible, and comparable biomarker data. Research collaboration will be instrumental in generating evidence to clarify the use of biomarkers in clinical trials and routine clinical practice. This should accelerate the development of In Vitro Diagnostics (IVD) biomarkers that: (1) support clinical screening, diagnosis, and prognosis, (2) track pharmacodynamic responses, and (3) monitor drug efficacy. Roche Diagnostics uses the collaborative NTK approach to accelerate and inform decision-making regarding the clinical utility and IVD development of medical value assays.

The required volume depends on the selected biomarker to be measured and sample type. Please see below for more details.

Although amyloid plaque deposition and tau tangles are the main pathological hallmarks of the disease, neuroinflammation, microglial overactivation and axonal/synaptic neurodegeneration to play an important role in AD pathogenesis. These pathological processes are complementary to the amyloid cascade hypothesis and are reflected by changes in biomarker levels measured in the NTK panel.

The NTKApp is a cloud based data analytics tool to curate, analyze and compare biomarker datasets and results - maximizing the interpretability of the generated results. It is deployed on the AD Workbench, a trusted cloud based platform for collaborative data science.

The NTKApp consists of three interlinked apps. This allows users to upload and curate, analyze, and compare biomarker datasets and results from all over the world in a few simple clicks. Thanks to the NTKApp built-in virtual machine, users have the option to import, shape, and run their own statistical analysis pipeline, which can later be shared within the NTK community.

The NTKCuration App module offers user-friendly data upload. Biomarker data needs quality control and standardization before being used in the NTKAnalysis App. - The NTKCuration App saves time and money because this automated data standardization process minimizes human error and allows comparability across datasets.

The NTKAnalysis App allows users to select from a suite of powerful descriptive statistics to gain immediate insight into their data. Outputs from these analyses are available in publication-quality tables and interpretable graphical visualizations, which can be saved locally.

The NTKMeta-Analysis App allows biomarker data to be compared with other data across the community. The cloud can be harnessed to select, stratify, and compare biomarkers and clinical characteristics in a global way. The NTKMeta-Analysis App also sheds light on shared data, resources, and objectives, providing support for existing and new clinical use cases based on collective evidence. This enables results to be contextualized and new hypotheses and evidence to be generated.

The NTKApp is a new neurological tool to exchange new ideas, encourage valuable research, and support industry partnerships – all to accelerate biomarker discovery and development.

No, measurements have to be performed in one of the four qualified NTK laboratories: LabCorp Indianapolis (USA), University of Gothenburg (Sweden), Microcoat (Penzberg, Germany) and TrigaS (Habach, Germany).